The impaired erythrocyte L-arginine/NO pathway in patients with type 2 diabetes

( views:155, downloads:0 )
Journal Title:
Volume 9, Issue 05, 2001
Key Word:

Abstract: Objective To investigate the changes in L Arginine Nitric oxide (L Arg NO) pathway of erythrocyte in patients with type 2 diabetes (DM). Methods Erythrocytes were isolated from venous blood taken from 19 patients with DM at admission and 10 normal controls. 3H L Arg transport was measured by radionuclide labeling. The content and activity of NO synthase (NOS) were measured after NOS had been isolated and purified, and the concentration of serum nitrate and nitrite (NO X) was measured.Results (1)The capacity of total L Arg transport in the DM group was lower than those in the control group maximum transport velocity (Vmax) decreased by 21%(P<0 01) and Michaelis constant (Km) increased by 18% (P<0 01). Compared with the control group, Vmax of system Y + L Arg transport decreased by 28% (P<0 01), and Km of the system Y +L L Arg transport increased by 10%(P<0 01) in the DM group. No significant difference was found with regard to Km of system Y + and Vmax of system Y +L in the two groups. (2)The content and activity of NOS in the DM group were lower than those in the control group (decreased by 15% and 34% respectively). (3)The concentration of serum NO X in the DM group was also found lower than that in the control group (decreased by 17%).Conclusion Multiple abnormal sites of L Arg NO pathway of erythrocytes were found in the patients with DM. The abnormality was able to decrease the production of NO, which may impair NO dependent vasodilation, increase the activity of platelets, accelerate the adhesion and aggregation of platelets, and promote the generation and development of diabetic angiopathy.

  • [1]Huszka M, Kaplar M, Rejto L, et al. The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res, 1997,86:173.
  • [2]Jubelin BC, Gierman JL. Erythrocytes may synthesize their own nitric oxide. Am J Hypertens, 1996,9:1214.
  • [3]Ribeiro ACM, Hanssen H, Kiessling K, et al. Transport of LArginine and the nitric oxide inhibitor NG-monomethyl-L-arginine in human erythrocytes in chronic renal failure. Clin Sci, 1997,93: 57.
  • [4]Chen LY, Mehta JL. Evidence for the presence of L-Arginine-Nitric Oxide pathway in human red blood cells: relevance in the effects of red blood cells on platelet function. J-Cardiovasc-Pharmacol, 1998,32:57.
  • [5]Deliconstantions G, Villiotou V, Stavrides JC, et al. Nitric oxide and peroxynitrite production by human erythrocytes: a causative factor of toxic anemia in breast cancer patients. Anticancer Res,1995,15: 1435.
  • [6]D eves R, Angelo S, Chavez P. N-Ethylmaleimide discriminates between two lysine transport systems in human erythrocytes. J Physiol, 1993,468:753.
  • [7]Bradford MM. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem, 1976,72:248.
  • [8]Veves-A, Akbari-Cm, Primavera-J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes, 1998,47:457.
  • [9]Cosentino-F, Luscher-TF. Endothelial dysfunction in diabetes mellitus. J-Cardiovasc-Pharmacol, 1998, 32 Suppl 3:S54.
  • [10]Angulo-J, Rodriguez-Manas-L, Peiro-C, et al. Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn-Schmiedebergs-ArchPharmacol, 1998,358: 529.
  • [11]Sobrevia L, Nadal A, Yiudilevich DL, et al. Activation of LArginine transport (system Y+ ) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J Physiol,1996,490:775.
  • [12]Kawaguchi-M,Koshimura-K,Murakami-Y,et al.Antihypertensive effect of insulin via nitric oxide production in the Zucker diabetic fatty rat, an animal model for non-insulin dependent diabetes mellitus. Eur-J-Endocrinol, 1999,140: 341.
  • [13]Nitenberg-A, Paycha-F, Ledoux-S, et al. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-Arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation, 1998,97: 736.
  • [14]Michimata T, Murakami M, Iriuchijima T,. Nitric oxide-dependent soluble guanylate cyclase activity is decreased in platelets from male NIDDM patients. Life Sci, 1996,59:1463.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615